A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized P… (NCT04215991) | Clinical Trial Compass
CompletedPhase 2
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants
United States, Australia, Georgia91 participantsStarted 2020-02-19
Plain-language summary
The primary objectives of this study are to assess the safety, tolerability, and pharmacokinetics (PK) of cefiderocol after single-dose administration in hospitalized pediatric participants 3 months to \< 12 years of age with suspected or confirmed aerobic Gram-negative bacterial infections and after multiple-dose administration in hospitalized pediatric participants 3 months to \< 18 years of age with suspected or confirmed complicated urinary tract infection (cUTI), hospital-acquired bacterial pneumonia (HABP), or ventilator-associated bacterial pneumonia (VABP).
Who can participate
Age range3 Months – 17 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Participant's parent(s) or legally authorized representative(s) (LAR) provides written informed consent in accordance with regional- and country-specific laws and regulations
✓. Participant provides written informed assent, when feasible (age of assent to be determined by institutional review board/independent ethics committee \[IRBs/IECs\] or be consistent with local legal requirements)
✓. Hospitalized participant is 3 months to \< 18 years of age at the time written informed consent/assent is obtained for the multiple-dose phase. Hospitalized participant is 3 months to \< 12 years of age at the time written informed consent/assent is obtained for the single-dose phase.
✓. Single-dose phase: Participant has a suspected or confirmed infection type (including but not limited to cUTI, complicated intra-abdominal infections \[cIAI\], pneumonia, HABP/VABP, and sepsis or bloodstream infections \[BSI\]) that requires hospitalization for treatment with IV antibiotics.
✓. If participant is a sexually active female of childbearing potential and has reached menarche or Tanner stage 3, participant agrees to use barrier contraception (including condom, diaphragm, or cervical cap) with spermicide or agrees to use a highly effective method of contraception (including contraceptive implant, injectable contraceptive, combination oral contraceptive, or an intrauterine \[IUD\] contraceptive device) from Screening up to 28 days after administration of the last dose of cefiderocol.
Exclusion criteria
What they're measuring
1
Number of Participants with Adverse Events in the Single Dose Phase
Timeframe: 28 days
2
Maximum Observed Plasma Concentration (Cmax) of Cefiderocol in the Single Dose Phase
Timeframe: Day 1, 1 (cohort 2 only), 3, 3.5 (cohort 2 only), 5, and 8 hours after the start of infusion
3
Area Under the Plasma Concentration Time Curve Extrapolated from Time 0 to Infinity (AUCinf) of Cefiderocol in the Single Dose Phase
Timeframe: Day 1, 1 (cohort 2 only), 3, 3.5 (cohort 2 only), 5, and 8 hours after the start of infusion
4
Apparent Terminal Elimination Half-life of Cefiderocol in the Single Dose Phase
Timeframe: Day 1, 1 (cohort 2 only), 3, 3.5 (cohort 2 only), 5, and 8 hours after the start of infusion
5
Number of Participants with Adverse Events in the Multiple Dose Phase
Timeframe: Up to 28 days after last dose (33 to 42 days depending on treatment duration)
6
Maximum Observed Plasma Concentration of Cefiderocol in the Multiple Dose Phase
Timeframe: During one of the dosing intervals from Day 5-14, 1 (cohort 2 1 and 2 only), 3, 3.5 (cohorts 1 and 2 only), 5, and 8 hours after the start of infusion
✕. Participant has a documented history of any hypersensitivity or allergic reaction to any β-lactam antibiotic (Note: for β-lactams, a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment.)
✕. Multiple-dose only: Participant has an infection caused only by a confirmed Gram-positive pathogen.
✕. Participant has a suspected or confirmed central nervous system (CNS) infection (for example, meningitis, brain abscess, shunt infection) or osteomyelitis (which would require prolonged antibiotic therapy).
✕. Participant has cystic fibrosis.
✕. Single-dose phase: Participant has moderate or severe renal impairment based on estimated glomerular filtration rate (eGFR) (based on the Schwartz equation if ≥ 3 months to \< 1 year of age and modified Bedside Schwartz equation if ≥ 1 to \< 18 years of age) of \< 60 milliliter (mL)/ minute (min)/1.73 square meters (m\^2)² at Screening .
✕. Participant has end-stage renal disease (ESRD), is on hemodialysis (HD), or receiving continuous venovenous hemofiltration (CVVH).
✕. Participant has experienced shock in the prior month or is in shock at the time of Screening.
✕. Participant has severe neutropenia or is severely immunocompromised.
Area Under the Plasma Concentration Time Curve Over the Dosing Interval Ï„ (AUC0-Ï„) of Cefiderocol in the Multiple Dose Phase
Timeframe: During one of the dosing intervals from Day 5-14, 1 (cohort 2 1 and 2 only), 3, 3.5 (cohorts 1 and 2 only), 5, and 8 hours after the start of infusion
8
Apparent Terminal Elimination Half-life of Cefiderocol in the Multiple Dose Phase
Timeframe: During one of the dosing intervals from Day 5-14, 1 (cohort 2 1 and 2 only), 3, 3.5 (cohorts 1 and 2 only), 5, and 8 hours after the start of infusion